Current Immunotherapy in Multiple Sclerosis
Immunology and Cell Biology 76:55-64, Bashir,K.&Whitaker,J.N., 1998
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Amelioration of Flulike Symptoms at the Onset of Interferon B-1b Therapy in Multiple Sclerosis by Low-Dose Oral Steriods is Related to a Decrease in Interleukin-6 Induction
Ann Neurol 44:682-685, Martinez-Caceres,E.M.,et al, 1998
Tourette Syndrome:Update and Review of the Literature
The Neurologist 4:188-195, Feigin,A.&Clarke,H., 1998
Gabapentin Does Not Interact with a Contraceptive Regimen of Norethindrone Acetate and Ethinyl Estradiol
Neurol 50:1146-1148, Eldon,M.A.,et al, 1998
Low-Dose Steroids Reduce Flu-Like Symptoms at the Initiation of INFB-1b in Relapsing-Remitting MS
Neurol 50:1910-1912, Rio,J.,et al, 1998
Incidence and Significance of Neutralizing Antibodies to Interferon Beta-1a in Multiple Sclerosis
Neurol 50:1266-1272, 12061998., Rudick,R.A.,et al, 1998
Clinicopath Conf
Subacute Sclerosing Panencephalitis, Case 15-1998, NEJM 338:1448-1456998., , 1998
Stroke and Use of Low-Dose Oral Contraceptives in Young Women,A Pooled Analysis of Two US Studies
Stroke 29:2277-2284, Schwartz,S.M.,et al, 1998
Interferon B Therapy for Multiple Sclerosis
Lancet 352:1486-1487, Goodkin,D.E., 1998
Interferons in the Treatment of Multiple Sclerosis,Do They Prevent the Progression of the Disease?
Arch Neurol 55:1578-1580,1583, Rice,G.&Ebers,G, 1998
Interferons Should be Used to Treat Most Patients with MS
Arch Neurol 55:1581-1583, Herndon,R.M.&Jacobs,L, 1998
Randomised Double-Blind Placebo-Controlled Study of Interferon B-1a in Relapsing/Remitting Multiple Sclerosis
Lancet 352:1498-1504,1486, PRISMS, 1998
Placebo-Controlled Multicentre Randomised Trial of Interferon B-1b in Treatment of Secondary Progressive Multiple Sclerosis
Lancet 352:1491-1497,1486, European Study Group on Interferon B-1b in Seconda, 1998
Oral Contraceptives and the Risk of Subarachnoid Hemorrhage:A Meta-Analysis
Neurol 51; 411-4181998., Johnson,S.C.,et al, 1998
High Risk of Cerebral-Vein Thromb in Carriers of Prothrombin-Gene Mutation & Users of Oral Contracept
NEJM 338:1793-1797, 18401998., Martinelli,I.,et al, 1998
Consequences of the Delayed Diagnosis of Ataxia-Telangiectasia
Pediatrics 102:98-100, Cabana,M.D.,et al, 1998
Rate of Pregnancy-Related Relapse in Multiple Sclerosis
NEJM 339:285-291, 3391998., Confavreux,C.,et al, 1998
Risk of Cerebral Sinus Thrombosis in Oral Contraceptive Users Who Are Carriers of Hered Prothrombotic Cond
BMJ 316:589-592, deBruijn,S.F.T.M.,et al, 1998
Effect of Steroids on Gd-Enhancing Lesions Before & During Beta Interferon 1a Trtm in Relapsing Remitting MS
Neurol 50:403-406, Gasperini,C.,et al, 1998
The Quality-of-Life Effects of Interferon Beta-1b in MS
Arch Neurol 54:1475-1480, Schwartz,C.E.,et al, 1997
Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997
Lifestyle-Associated Risk Factors for Acute Brain Infarction Among Persons of Working Age
Stroke 28:26-30, Haapaniemi,H.,et al, 1997
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Interferon Beta Results in Immediate Reduction of Contrast-Enhanced MRI Lesions in MS Pts Followed by Weekly MRI
Neurol 48:1446-1448, Calabresi,P.A.,et al, 1997
Character of MRI Response to Trtm with Interferon Beta-1B:Enhancing MRI Lesion Freq as Prim Outcome Measure
Neurol 49:862-869, Stone,L.A.,et al, 1997
Impact of Interferon Beta-1A On Neurologic Disability in Relapsing Multiple Sclerosis
Neurol 49:358-363, Rudick,R.A.,et al, 1997
Anticytokine Antibodies in Beta Interferon-Trated MS Patients and the Need for Testing
Neurol 49:647-650, Pachner,A.R., 1997
Distinction of Idiopathic Parkinson's Dis from Multi-Syst Atrophy by Stim of Growth-Hormone Release w Clonidine
Lancet 349:1877-1881, Kimber,J.R.,et al, 1997
Use of Low-Dose Oral Contraceptives and Stroke in Young Women
Ann Int Med 127:596-603, Schwartz,S.M.,et al, 1997
Case-Control Study of Oral Contraceptives & Risk of Thromboembolic Stroke
BMJ 315:1502-1504, Heinermann,L.A.J.,et al, 1997
Neutralizing Antibodies During Treatment of Multiple Sclerosis with Interferon Beta-1b
IFNB MS Study Group & UBC MS. MRI Analysis Group, Neurol 47:889-8946., , 1996
Guidelines for Physicians with Patients on IFNB-1b:The Use of an Assay for Neutralizing Antibodies (NAB)
Neurol 47:865-866, Paty,D.,et al, 1996
Nonsystemic Vasculitic Mononeuropathy Multiplex, Cryoglobulinemia, and Hepatitis C
Muscle & Nerve 19:1596-1602996., David,W.S.,et al, 1996
Interferon Beta in Multiple Sclerosis
BMJ 313:1159, 1157, 1195996., Richards,R.G., 1996
History of Migraine and Risk of Cerebral Ischaemia in Young Adults
Lancet 347:1503-1506, Carolei,A.,et al, 1996
Progressive Multifocal Leukoencephalopathy:Clinical and MR Response to Treatment
AJNR 17:597-600, Garrels,K.,et al, 1996
Medication for Children with Attentional Disorders
Pediatrics 98:301-304, Perrin,J.,et al, 1996
New Antiepileptic Drugs
NEJM 334:1583-1590, Dichter,M.A.&Brodie,M.J., 1996
Long-term Prognosis in Cerebral Venous Thrombosis:Follow-up of 77 Patients
Stroke 27:243-246, Preter,M.,et al, 1996
Side Effect Profile of Interferon Beta-1b in MS:Results of an Open Label Trial
Neurol 46:552-554, Neilley,L.K.,et al, 1996
Stroke in Users of Low-Dose Oral Contraceptives
NEJM 335:8-15, 531996., Petitti,D.B.,et al, 1996
Ischaemic Stroke and Combined Oral Contraceptives:Results of an International, Multicentre, Case-Control Study
Lancet 348:498-505, Poulter,N.R.,et al, 1996
Cerebral Venous Sinus Thrombosis Associated with Factor V Gene Mutation
JNNP 61:204-205, Kimber,T.,et al, 1996
Antiepileptic Medication and Oral Contraceptive Interactions:A National Survey of Neurologists and Obstetricians
Neurol 46:1534-1539, Krauss,G.L.,et al, 1996
Management of Patients Receiving Interferon Beta-1b for MS:Report of a Consensus Conf
Neurol 46:12-18, Lublin,F.D.,et al, 1996
Neuropathic Pain of Peripheral Origin:Advances in Pharmacologic Treatment
Neurol 45 (suppl 8) :s17-s25995., Galer,B.S., 1995
Primary Prevention of Stroke
NEJM 333:1392-1400, Bronner,L.L.,et al, 1995
The Interferons:Biological Effects, Mechanisms of Action, and Use in Multiple Sclerosis
Ann Neurol 37:7-15, Weinstock-Guttman,B.,et al, 1995
New Treatments for Multiple Sclerosis
BMJ 310:345-346, McDonald,W.I., 1995